Claret Asset Management Corp Abb Vie Inc. Transaction History

Claret Asset Management Corp

$611 Million
Q3 2024

A detailed history of Claret Asset Management Corp transactions in Abb Vie Inc. stock. As of the latest transaction made, Claret Asset Management Corp holds 130,633 shares of ABBV stock, worth $22.9 Million. This represents 4.22% of its overall portfolio holdings.

Number of Shares

130,633

Previous 134,234 2.68%

Holding current value

$22.9 Million

Previous $23 Million 12.04%

% of portfolio

4.22%

Previous 4.1%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$163.84 - $199.33 $589,987 - $717,787	-3,601 Reduced 2.68%	130,633 $25.8 Million
Q2 2024 Aug 14, 2024	SELL	$154.79 - $180.76 $909,391 - $1.06 Million	-5,875 Reduced 4.19%	134,234 $23 Million
Q1 2024 Apr 29, 2024	SELL	$159.82 - $182.1 $348,567 - $397,160	-2,181 Reduced 1.53%	140,109 $25.5 Million
Q4 2023 Feb 12, 2024	SELL	$137.6 - $154.97 $64,396 - $72,525	-468 Reduced 0.33%	142,290 $22.1 Million
Q3 2023 Nov 13, 2023	SELL	$133.59 - $154.65 $183,819 - $212,798	-1,376 Reduced 0.95%	142,758 $21.3 Million
Q2 2023 Aug 09, 2023	SELL	$132.51 - $164.9 $135,292 - $168,362	-1,021 Reduced 0.7%	144,134 $19.4 Million
Q1 2023 Apr 18, 2023	SELL	$144.61 - $166.54 $307,007 - $353,564	-2,123 Reduced 1.44%	145,155 $23.1 Million
Q4 2022 Feb 07, 2023	SELL	$138.31 - $165.87 $62,654 - $75,139	-453 Reduced 0.31%	147,278 $23.8 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $275,398 - $315,864	-2,052 Reduced 1.37%	147,731 $19.8 Million
Q2 2022 Jul 28, 2022	SELL	$137.62 - $174.96 $861,914 - $1.1 Million	-6,263 Reduced 4.01%	149,783 $22.9 Million
Q1 2022 Apr 04, 2022	SELL	$131.98 - $163.75 $1.64 Million - $2.04 Million	-12,428 Reduced 7.38%	156,046 $25.3 Million
Q4 2021 Feb 07, 2022	SELL	$107.43 - $135.93 $45,228 - $57,226	-421 Reduced 0.25%	168,474 $22.8 Million
Q3 2021 Dec 02, 2021	BUY	$106.4 - $120.78 $1.22 Million - $1.39 Million	11,511 Added 7.31%	168,895 $18.2 Million
Q2 2021 Aug 09, 2021	BUY	$105.21 - $117.21 $1.1 Million - $1.23 Million	10,455 Added 7.12%	157,384 $17.7 Million
Q1 2021 May 04, 2021	SELL	$102.3 - $112.62 $105,880 - $116,561	-1,035 Reduced 0.7%	146,929 $15.9 Million
Q4 2020 Feb 02, 2021	BUY	$80.49 - $108.67 $1.02 Million - $1.38 Million	12,716 Added 9.4%	147,964 $15.9 Million
Q3 2020 Oct 29, 2020	SELL	$85.91 - $100.83 $89,088 - $104,560	-1,037 Reduced 0.76%	135,248 $11.8 Million
Q2 2020 Aug 06, 2020	SELL	$73.37 - $98.18 $309,841 - $414,614	-4,223 Reduced 3.01%	136,285 $13.4 Million
Q1 2020 Apr 06, 2020	SELL	$64.5 - $97.79 $394,030 - $597,399	-6,109 Reduced 4.17%	140,508 $10.7 Million
Q4 2019 Jan 07, 2020	SELL	$72.13 - $90.25 $43,350 - $54,240	-601 Reduced 0.41%	146,617 $13 Million
Q3 2019 Oct 11, 2019	BUY	$62.98 - $75.72 $32,623 - $39,222	518 Added 0.35%	147,218 $11.1 Million
Q2 2019 Jul 24, 2019	SELL	$65.7 - $83.98 $80,088 - $102,371	-1,219 Reduced 0.82%	146,700 $10.7 Million
Q1 2019 Apr 29, 2019	SELL	$77.14 - $90.79 $21,599 - $25,421	-280 Reduced 0.19%	147,919 $11.9 Million
Q4 2018 Feb 07, 2019	SELL	$77.85 - $96.01 $440,163 - $542,840	-5,654 Reduced 3.67%	148,199 $13.7 Million
Q3 2018 Oct 30, 2018	BUY	$88.91 - $98.84 $287,268 - $319,352	3,231 Added 2.15%	153,853 $14.6 Million
Q2 2018 Aug 13, 2018	BUY	$89.78 - $106.23 $215,382 - $254,845	2,399 Added 1.62%	150,622 $14 Million
Q1 2018 May 08, 2018	SELL	$92.01 - $123.21 $944,390 - $1.26 Million	-10,264 Reduced 6.48%	148,223 $14 Million
Q4 2017 Mar 27, 2018	BUY	$89.56 - $98.21 $14.2 Million - $15.6 Million	158,487	158,487 $15.3 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Claret Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Claret Asset Management Corp with notifications on news.

Account

Claret Asset Management Corp Abb Vie Inc. Transaction History